Esposito Pamela 4

What Happened

• Pamela Esposito, a director of Kymera Therapeutics, was granted a derivative award (stock option) covering 6,068 shares on 2026-06-24. The Form 4 reports the acquisition value as $0.00 (typical for option grants) and the transaction is recorded as an award/grant (code A), not a market purchase or sale.

Key Details

• Transaction date: 2026-06-24; filing date: 2026-06-25 (timely).
• Reported acquisition: 6,068 shares at $0.00 (derivative instrument — stock option).
• Shares owned after transaction: not specified in the provided data.
• Footnote (F1): The shares underlying this stock option vest in full upon the earlier of (i) June 24, 2027 or (ii) the date of the next annual meeting of stockholders.
• No indication of an immediate exercise or sale; strike/exercise price is not disclosed in the summary.

Context

• This is a typical director equity grant used for compensation and retention. Because it’s a derivative award that vests in the future and was not exercised or sold, it does not represent an immediate purchase or liquidation of shares. Such grants are common and should be interpreted as compensation-related rather than a direct market signal.